Company intelligence / Profile preview

Apollo

Cambridge, United Kingdom

Ownership: Public · APO
Development stage: Other

Overview

Apollo Therapeutics has more than 20 programs in its pipeline, including six in clinical development, with a focus on immunology, oncology, and rare diseases. Clinical acquisition includes anti-IL-18 mAb camoteskimab (AP43), targeting atopic dermatitis and other conditions.

Therapeutic areas: OncologyRare DiseasesDermatologyImmunology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

University of CambridgeImperial College LondonUniversity College London (UCL)King's College LondonInstitute of Cancer ResearchAstraZenecaGSKJohnson & Johnson

Financials

Market cap: $74.7B
Total revenue: $4.9B
Enterprise value: $-164.2B

Beyond the preview

Go deeper on Apollo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apollo.

Explore the full profile